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Commentary on ‘Early Results from the ENGAGE Registry: Real World
Performance of the Endurant Stent Graft for Endovascular AAA Repair in 1262
Patients’
E.L.G. Verhoeven*, A. Katsargyris
Department of Vascular and Endovascular Surgery, Klinikum Nürnberg, Breslauer Strasse 201, 90471 Nürnberg, GermanyThe Endurant (Medtronic, Santa Rosa, California, USA) Stent
Graft Natural Selection Global Postmarket Registry (ENGAGE) is
unprecedented because of its magnitude. In this report, the authors
describe early results in 1262 patients treated with the Endurant
stent-graft in 79 sites around the world. This large registry clearly
demonstrates the commitment of the manufacturer to provide ‘real
world’ data to the vascular community. We seem to move away
from randomised trials comparing open and endovascular repair
(EVAR) to focus on advances in EVAR. Clearly, we have reached
a point of acceptance between two validated techniques in the
treatment of infrarenal abdominal aortic aneurysms.
The authors document perioperative (30 days) outcomes for the
total patient cohort, but also provide 1-year follow-up results for
39.6% (500/1262) of the patients. It is no surprise that the results
are excellent. Most of the currently available third-generation
stent-grafts would probably match these outcomes. Complica-
tions leading to higher re-intervention rates compared to open
repair usually occur after the ﬁrst year or even only after 3e5 years
postoperatively.1e3 We do not contest the quality of the results, and
the authors do acknowledge that longer-term results need to be
awaited, but the conclusion is overrated. As mentioned, we
completely agree with the magnitude of the effort (unprece-
dented), but not that the results are (already?) promising (what?)
or that the graft is safe and effective yet. Not that we doubt on the
quality of the graft, but technically speaking we just need longer-
term outcomes before having proven safety and effectiveness.
Unfortunately, such premature conclusions are drawn too easy
with new generation stent-grafts (or with current new concept
stent-grafts).
The ENGAGE registry aims at reporting ‘real world’ results, by its
magnitude and the many centres throughout the world. Never-
theless, we would argue that these are still larger and experienced
centres. It actually positively surprises us that only 17.9% of the
patients were treated outside instructions for use (IFU) criteria, inDOI of original article: 10.1016/j.ejvs.2012.07.005.
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the other hand, the inclusion criteria for the Endurant are very
liberal, based on extensive bench testing by the manufacturer.
Necks as short as 10 mm length, and/or severe angulations are part
of the IFU’s. To demonstrate effectiveness and safety, patients with
adverse anatomy (inside the liberalised IFU’s and outside IFU’s)
treated with the Endurant should be studied separately and in the
long term. In addition, one has to be careful not to send the wrong
message to the community, because in the real ‘real world’, most
cases are performed in low volume centres.5,6 Before treating
patients outside these already liberal and not clinically proven
IFU’s, one needs to balance the risks of EVAR with the Endurant in
challenging anatomy with other therapeutic options, such as open
repair, fenestrated stent-grafting or even chimney techniques.
Broadening eligibility is not a goal in itself and, more than ever,
with so many options around, we must try hard to ﬁnd the best
solution for each individual patient, and not for the doctor.
In conclusion, we absolutely recognise the magnitude of the
registry and congratulate both the manufacturer and all investi-
gators. We eagerly await longer-term results that could demon-
strate safety and effectiveness of the Endurant, especially in
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